Radiopharm Theranostics (ASX:RAD) said the first in-human findings from the ongoing Phase 0/1 HEAT trial evaluating its radiotherapeutic candidate, lutetium-177-RAD202, showed "meaningful" tumor uptake and a favorable safety profile at the lowest dose level of 30 millicurie (mCi), according to a Monday Australian bourse filing.

Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation, while no dose-limiting toxicities or treatment discontinuations due to adverse events were observed, per the filing.

The radiotherapeutic candidate was generally well tolerated in the first three treated patients, with predominantly grade one to two treatment-emergent adverse events, the filing added.

Radiopharm Theranostics' shares rose past 2% in recent trading on Monday.